Correlation between methylation level of SLC19A1 promoter region and methotrexate metabolism in adult acute lymphoblastic leukemia

被引：0
|
作者：
Huang, Xianqi [1 ]
Hao, Qishan [1 ]
Fang, Qiuyun [1 ]
Zhang, Ping [1 ]
Wei, Hui [1 ]
Wang, Ying [1 ]
Wang, Jianxiang [1 ]
Mi, Yingchang [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, Tianjin 300020, Peoples R China
来源：
PHARMACOGENOMICS | 2023年 / 24卷 / 05期
关键词：
acute lymphoblastic leukemia; adult; high-dose MTX; methylation; FOLATE CARRIER GENE; EXPRESSION; RFC1;
D O I：
10.2217/pgs-2022-0169
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aims: To analyze the methylation level in the promoter region of SLC19A1 in adult acute lymphoblastic leukemia (ALL) patients, and explore the relationship between methotrexate (MTX) drug metabolism and SLC19A1 methylation. Methods: The methylation levels of the SLC19A1 promoter region in 52 adult ALL patients who received high-dose MTX chemotherapy were retrospectively analyzed in combination with clinical indicators and plasma MTX concentration. Results: Methylation levels of 17 CpG units were differently correlated with clinical parameters of ALL patients including gender, age, immunophenotype and Philadelphia chromosome status. Patients with delayed MTX drug excretion had higher methylation levels in the SLC19A1 promoter region. Conclusion: The methylation may affect the MTX plasma level and adverse reactions, which may predict patients at risk of adverse reactions after high-dose MTX therapy.
引用
收藏
页码：261 / 268
页数：8
相关论文
共 50 条
  • [21] ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia
    Agirre, X
    Román-Gómez, J
    Jiménez-Velasco, A
    Garate, L
    Montiel-Duarte, C
    Navarro, G
    Vázquez, I
    Zalacain, M
    Calasanz, MJ
    Heiniger, A
    Torres, A
    Minna, JD
    Prósper, F
    ONCOGENE, 2006, 25 (13) : 1862 - 1870
  • [22] Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8
    Hu, Xiaobo
    Wei, Hui
    Xiang, Laiman
    Chertov, Oleg
    Wayne, Alan S.
    Bera, Tapan K.
    Pastan, Ira
    LEUKEMIA RESEARCH, 2013, 37 (11) : 1551 - 1556
  • [23] ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia
    X Agirre
    J Román-Gómez
    A Jiménez-Velasco
    L Garate
    C Montiel-Duarte
    G Navarro
    I Vázquez
    M Zalacain
    M J Calasanz
    A Heiniger
    A Torres
    J D Minna
    F Prósper
    Oncogene, 2006, 25 : 1862 - 1870
  • [24] An investigation of methylation pattern changes in the IKZF1 promoter in patients with childhood B-cell acute lymphoblastic leukemia
    Rahmani, Mina
    Fardi, Masoumeh
    Hagh, Majid Farshdousti
    Feizi, Abbas Ali Hosseinpour
    Talebi, Mehdi
    Solali, Saeed
    BLOOD RESEARCH, 2019, 54 (02) : 144 - 148
  • [25] The Role of SLC22A1 and Genomic Ancestry on Toxicity during Treatment in Children with Acute Lymphoblastic Leukemia of the Amazon Region
    Fernandes, Sweny de S. M.
    Leitao, Luciana P. C.
    Cohen-Paes, Amanda De N.
    Gellen, Laura P. A.
    Pastana, Lucas F.
    de Carvalho, Darlen C.
    Modesto, Antonio A. C.
    da Costa, Ana C. A.
    Wanderley, Alayde, V
    de Lima, Carlos H., V
    Pereira, Esdras E. B.
    Fernandes, Marianne R.
    Burbano, Rommel M. R.
    de Assumpcao, Paulo P.
    dos Santos, Sidney E. B.
    dos Santos, Ney P. C.
    GENES, 2022, 13 (04)
  • [26] TRANSLOCATION BETWEEN CHROMOSOME-1 AND CHROMOSOME-19 IN ACUTE LYMPHOBLASTIC-LEUKEMIA
    GARRY, MB
    GRINDLEY, RM
    CANCER GENETICS AND CYTOGENETICS, 1984, 13 (04) : 343 - 344
  • [27] CDKN2B, SLC19A3 and DLEC1 promoter methylation alterations in the bone marrow of patients with acute myeloid leukemia during chemotherapy
    Hong, Qingxiao
    Li, Yirun
    Chen, Xiaoying
    Ye, Huadan
    Tang, Linlin
    Zhou, Annan
    Hu, Yan
    Gao, Yuting
    Chen, Rongrong
    Xia, Yongming
    Duan, Shiwei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2016, 11 (05) : 1901 - 1907
  • [28] Erratum: ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia
    X Agirre
    J Román-Gómez
    A Jiménez-Velasco
    L Garate
    C Montiel-Duarte
    G Navarro
    I Vázquez
    M Zalacain
    M J Calasanz
    A Heiniger
    A Torres
    J D Minna
    F Prósper
    Oncogene, 2013, 32 : 803 - 803
  • [29] Transcription regulatory polymorphism-43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy
    Chatzikyriakidou, Anthoula
    Georgiou, Ioannis
    Voulgari, Paraskevi V.
    Papadopoulos, Christos G.
    Tzavaras, Theodoros
    Drosos, Alexandros A.
    RHEUMATOLOGY INTERNATIONAL, 2007, 27 (11) : 1057 - 1061
  • [30] The association between methylation in specific cpg sites of slc6a4 gene promoter region and prognosis of acs patients with different level of burnout
    Zhang, H.
    Zhang, M.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2663 - 2663
12345